The model for end-stage liver disease (MELD) has replaced the role of the ChildeTurcotteePugh system as a more commonly used system in evaluating the severity of liver dysfunction in patients with chronic liver disease, owing to its superior ability to predict survival. The United Network of Organ Sharing (UNOS) in the USA has used the MELD system for prioritizing donor grafts in advanced cirrhotic patients awaiting liver transplantation since 2002. Serum sodium level is another important prognostic predictor in cirrhosis. Consequently, by incorporating serum sodium into the original MELD, the MELD-Na, MELDNa, the MELD-to-sodium ratio (MESO) index, and the ReFit MELDNa were proposed in an attempt to improve the predictive ability of the original MELD. Nevertheless, there are some limitations of the MELD-based systems that need to be refined. The MELD-based systems merely use laboratory data as parameters for the equation, therefore, any lack in unification and standardization of laboratory methods will result in inconsistent data that affect the prioritization of liver transplantation. Furthermore, the MELD system includes creatinine as a parameter, and serum creatinine level may represent different degrees of renal dysfunction in men and women. Therefore, these limitations may compromise the fair process of organ allocation for female cirrhotic patients. Currently, the application of the MELD system has been extended to tumor staging of hepatocellular carcinoma. Several studies have replaced the ChildeTurcotteePugh system with the MELD as a parameter, indicating that the use of different criteria of liver dysfunction in cancer staging may enhance prognostic accuracy. Although the outcome data of the modified staging systems need to be confirmed, the concept of using the MELD as a reference system for evaluating the severity of liver dysfunction has globally become an important issue.
Introduction
Chronic liver inflammation, a consequence of chronic virus infection or alcohol consumption, may subsequently develop into liver cirrhosis arising from continuous liver injury. Advanced liver cirrhosis may present with ascites formation, coagulopathy, elevated serum bilirubin level, decreased serum albumin level, presence of hepatic encephalopathy, and cirrhotic cardiomyopathy. 1, 2 Deterioration of these clinical parameters may indicate liver failure and contributes to a major cause of death in patients with liver cirrhosis. 3 The ChildeTurcotteePugh (CTP) system was initially used to evaluate the severity of liver dysfunction and predict survival in these chronic liver disease patients (Table 1) . 4 The model for end-stage liver disease (MELD) scoring system was proposed as the major system for organ allocation in cirrhotic patients awaiting liver transplantation, owing to its better ability to predict accurately short-term outcome compared with the CTP system. 5 In recent years, many study groups have tried to enhance the prognostic ability of the MELD system by incorporating new parameters or adjusting the original equation. In addition, the clinical implications of the MELD system have been extended beyond its original purpose. In this review article, we highlight the development of the MELD and MELD-derived systems, the clinical applications in organ allocation and other purposes, and associated limitations and future perspectives.
Development of MELD system
As a consequence of continuous liver insult due to chronic inflammation, limited treatment options are effective for patients with advanced cirrhosis. In recent decades, liver transplantation has become the only definite treatment for advanced cirrhosis with the possibility of cure. Even so, major challenges in the shortage of liver donor grafts have limited its priority in clinical practice. In order to optimize organ allocation to patients in utmost need (the "sickest first" policy), systems for evaluating the outcome of these patients on the transplantation list have been developed. The MELD scoring system was initially proposed in 2000 to predict mortality in cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt. 6 The MELD scoring system provided continuous values by a logarithmic calculation of three laboratory-available parameters, serum bilirubin, international normalized ratio (INR) of prothrombin time, and creatinine level (Table 1) . A major breakthrough of the MELD system was the introduction of renal function into the prognostic model. Renal dysfunction is often seen in patients with liver cirrhosis and the development of hepatorenal syndrome is a consequence of deteriorated residual liver function in advanced cirrhotic patients. 7 Profound renal dysfunction usually indicates an extremely poor prognosis in these patients. 8 Therefore, incorporation of serum creatinine may further enhance its prognostic ability. Notably, the MELD had been implemented as the major reference system for organ allocation in liver transplantation by the United Network of Organ Sharing (UNOS) in the USA to prioritize advanced cirrhotic patients, due to its better ability to predict survival in comparison with the CTP classification. 5 The MELD system had several clear advantages over the CTP classification. First, it only includes objective parameters that eliminate interobserver bias. In addition, compared to the CTP classification, MELD provides larger grading scales that assist in better discrimination of the severity of liver dysfunction, owing to its status as a continuous entity. After 2002, ample evidence subsequently confirmed the prognostic role of the MELD system in different clinical settings.
Proposal of the MELD-derived systems: making the MELD better
Since the introduction of the MELD system, many study groups have developed modified systems derived from the original MELD to enhance its prognostic ability. Serum sodium (Na) level has been recognized as an important prognostic indicator in cirrhosis, and hyponatremia is often associated with portal hypertension, ascites formation, hepatorenal syndrome, and liver-related mortality. 9e12 Arising from the added effect of hyponatremia on the risk of death in cirrhotic patients, the MELD-Na was proposed in 2006 (Table 1) . 13 The MELDNa incorporated serum Na into the equation by adding additional scores to the original MELD in patients with serum Na between 120 mEq/L and 134 mEq/L. The MELD-Na prioritizes hyponatremia patients on the transplantation list over those with the same MELD score but with normal serum Na level. With the incorporation of serum Na level, MELD-Na could more accurately predict the survival of cirrhotic patients and shorten the waiting time on the transplant list. However, there are still some limitations with the MELD-Na system, and an important issue is that the role of hyponatremia on the added risk of death is abolished with the increase of MELD score. Kim et al have proposed the MELDNa and corrected this limitation by incorporating serum Na to the original MELD equation; the MELDNa also eliminates the effect of hyponatremia on the risk of death in patients with high MELD scores ( Table 1 ).
14 The MELD-to-sodium ratio (MESO) index was proposed by our study group to amplify the opposing effect of MELD score and serum Na in survival prediction ( Table 1 ). The MESO index provides better prognostic ability when compared with the original MELD system, and it also correlates well with hepatic venous pressure gradient and CTP score. 15 The ReFit MELDNa was introduced in 2011 by emphasizing the major key points described by previous equations (Table 1) . 16 Similarly, it uses serum bilirubin, INR of prothrombin time and serum creatinine as the basis of the equation. First, it optimizes the coefficients and the upper and lower bounds of the three parameters according to the linear relationship in the Cox model with the risk of death. Second, it incorporates serum Na into the equation to enhance the prognostic ability in patients with hyponatremia. Lastly, the decreased impact of serum Na on mortality when serum bilirubin increases is also considered and is described in the equation. The ReFit MELDNa more accurately discriminates the mortality of patients on the waiting list when compared with the original MELD and MELDNa; it has ultimately affected up to 12% of patients on the transplantation list. 16 Alternatively, previous studies have focused on the degree of liver dysfunction by a single-point determination of the score but have neglected the continuous change in MELD score throughout the course of the disease. The change in MELD score over time (DMELD) has previously been proposed and defined as the change in MELD score per interval period of time (months) ( Table 1) . 17 An increasing DMELD score is associated with the onset of ascites and hepatic encephalopathy and is superior to the initial MELD and CTP scores in predicting intermediate outcome in advanced cirrhotic patients. 18 Many complications may accompany the ongoing deterioration of residual liver function and the development of eventual hepatic failure. Intractable hepatic encephalopathy, bleeding esophageal varices, spontaneous bacterial peritonitis, and ascites formation are major complications in cirrhosis and are also important prognostic predictors in these patients. Supporting evidence shows that the complications in these patients may not necessarily correlate well with the MELD score, 19, 20 suggesting that these patients may be potentially missed in the MELD era. Studies have shown that with the incorporation of hepatic encephalopathy 21 and ascites formation, 22 the modified MELD systems would enhance predictive ability independent of the MELD score.
Limitations of the MELD and MELD-derived systems
Despite the suggestion that MELD-derived systems could more accurately predict survival and discriminate the severity of liver dysfunction when compared with the CTP system, there are still some real drawbacks to this proposition. The MELD-derived systems exclusively rely on objective laboratory data, and variations in laboratory methods potentially affect its accuracy. The compensated kinetic Jaffe, O'Leary modified Jaffe, enzymatic, and standard kinetic Jaffe methods have been used to measure serum creatinine. There is negligible agreement among these different assays in the measurement of serum creatinine for the calculation of MELD score. 23 Furthermore, between-laboratory variations in INR measurement may result in substantial changes in the MELD score independent of the severity of illness, and may significantly affect prioritization for liver transplantation. 24 Further laboratory methods should be united and standardized in the future in an attempt to facilitate a fair process of organ allocation. Another limitation of the MELD-derived systems is that the serum creatinine may represent different degrees of renal dysfunction between the sexes. Women have lower glomerular filtration rate than men for the same serum creatinine value, yet this is not accounted for in the MELD and MELD-derived systems. 25 Using the same serum creatinine level for calculating the MELD score lowers the prioritization for liver transplantation for female cirrhotic patients. Therefore, a corrected-creatinine MELD system was developed in an attempt to adjust creatinine level to the same glomerular filtration rate in female patients as in male patients. This prioritizes female patients for liver transplantation, but may only be justified in predicting intermediate-term (9-and 12-month), but not short-term (3-and 6-month) mortality. 26 Despite its drawbacks and the proposal of many other MELD-derived systems, the original MELD system is still the major organ allocation system for liver transplantation used in most countries. The main reason is that the MELD system avoids interobserver bias with only objective parameters in the equation; however, some other studies comparing the superiority of the different MELD-derived systems have suggested inconsistent results. 27e30 In Taiwan, an endemic area for hepatitis B, the MELD system is also the system used to prioritize patients for liver transplantation. Although the outcome data of patients on the transplantation list by using the MELD allocation system in Taiwan still need to be investigated, this strategy provides a fair process of allocating donor organs without taking the personal decisions of physicians into consideration.
MELD in hepatocellular carcinoma
Currently, the application of the MELD system has been expanded to an extent beyond its original design. A substantially high proportion of cirrhotic patients may eventually develop hepatocellular carcinoma (HCC), therefore, the MELD-derived systems played a crucial role in outcome prediction in HCC patients in terms of evaluating the degree of liver dysfunction in addition to tumoral factors. 31e33 The Barcelona Clinic Liver Cancer (BCLC), 34, 35 Cancer of the Liver Italian Program (CLIP), 36 and Japan Integrated Scoring (JIS) 37 are all tumor staging systems for HCC and all include CTP classification as a parameter of representing liver function. We have modified the BCLC, CLIP and JIS classification systems by replacing the CTP classification to the MELD scores in evaluating the functional liver reserve of HCC patients ( Table 2) . 38 The MELD-based CLIP and MELD-based JIS staging systems have improved overall prognostic ability when compared with the original systems. More recently, we have developed a new tumor staging system by incorporating different combinations of prognostic predictors, including tumoral factors [total tumor volume, liver function (CTP, MELD, MELDNa and MELD-Na) and tumor behavior (presence of vascular invasion and serum a-fetoprotein level)] and compared them with the original BCLC, CLIP, JIS, and Tokyo staging systems and each other in terms of outcome prediction. The Taipei Integrated Scoring System, 27 which encompasses total tumor volume, CTP and serum a-fetoprotein level as parameters, displayed the best prognostic ability when compared with the original systems and other combinations in terms of outcome prediction (Table 2) . 33 Although further prospective studies are needed to validate the role of MELD in HCC staging, the notion of the MELD to replace the CTP as the parameter representing liver functional reserve may change future management guidelines for HCC. 39 
Future perspectives
The MELD system was created to optimize the allocation of donor organ grafts in advanced cirrhotic patients awaiting liver transplantation, due to its enhanced ability in predicting short-term outcome. However, the role in predicting posttransplant mortality was not considered and established when developing such systems in organ allocation. The MELD system did not well correlate with post-transplant mortality in patients receiving transplantation. 40 General health condition, other chronic comorbidity and most importantly, donor factors, all may have an impact on post-transplant mortality. Systems for selecting the highest pretransplant mortality and lowest post-transplant mortality should be developed to optimize the allocation of organs to those who are most in need, and will have the maximal benefit upon receiving the organ.
The MELD system has now expanded its clinical indications beyond its original use. An important issue that may require further attention is that the MELD system was originally created in patients who did not have acute or reversible complications. Therefore, the MELD score would more precisely represent the current liver function status after treating the acute complications that develop in these patients. Whether the MELD system and its derived models can be equally applied as a tool for outcome prediction in different clinical scenarios beyond their original aim requires additional study for further clarification.
Although the MELD system is considered to represent more accurately liver dysfunction in terms of outcome prediction, the CTP is still the main system in evaluating the degree of liver dysfunction in HCC tumor staging systems.
Results from recent studies have demonstrated enhanced accuracy of predicting long-term outcome in HCC patients by replacing the CTP system with the MELD system. 38 Additional prospective studies should be performed to validate the role of the MELD system in HCC, and management guidelines for HCC may need to be modified to provide optimal recommendations for cancer patients.
